---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-020521"
form_type: "8-K"
ticker: "ALXO"
cik: "0001810182"
company_name: "ALX ONCOLOGY HOLDINGS INC"
filed_at: "2022-10-31T23:59:59+00:00"
generated_at: "2026-06-22T21:51:30.657605+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ALX Oncology secures up to $100M non-dilutive loan facility with Oxford and SVB, extends cash runway to mid-2025

## Summary
- Initial draw of $10M from first $50M tranche; remaining $40M available through end of 2023.
- Up to $50M additional in three tranches: $12.5M each tied to milestones for evorpacept and preclinical candidate, $25M at lenders' discretion.
- Interest-only period of 36 months (extendable to 48); total term 59 months; no warrants or financial covenants.
- Matures October 2027; floating SOFR-based interest rate with minimum 8.58% per annum.
- Proceeds support evorpacept development and general working capital, extending cash runway to mid-2025.

## SEC filing metadata
- accession: 0000950170-22-020521
- form_type: 8-K
- ticker: ALXO
- cik: 0001810182
- company_name: ALX ONCOLOGY HOLDINGS INC
- filed_at: 2022-10-31T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810182/000095017022020521/0000950170-22-020521-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810182/000095017022020521/alxo-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-020521
- JSON: https://secwatch.observer/filing/0000950170-22-020521.json
- Plain text: https://secwatch.observer/filing/0000950170-22-020521.txt

## Key facts
- Material Agreements
  ALX ONCOLOGY HOLDINGS INC entered into Loan and Security Agreement with Oxford Finance LLC and Lenders valued at up to $100 million aggregate principal amount, with $10 million initial funding (effective 2022-10-27).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Oxford Finance LLC and Lenders
  - Value: up to $100 million aggregate principal amount, with $10 million initial funding
  - Effective: 2022-10-27
  source text: On October 27, 2022, ALX Oncology Holdings Inc., a Delaware corporation (the “Company”), entered into a loan and security agreement (the “Loan Agreement”) among Oxford Finance LLC, as collateral agent (“Agent”), and Oxford Finance LLC, Oxford Finance Credit Fund II LP, and Silicon Valley Bank, as the lenders from time to time party thereto (“Lenders”), ALX Oncology Inc., a Delaware corporation (“ALX”), Alexo Therapeutics International, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Alexo”), and Sirpant Therapeutics, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“Sirpant” and, together with ALX and Alexo, the “Borrowers”), and the Company as a guarantor.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810182/000095017022020521/0000950170-22-020521-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.